SharesGrow.com Intrinsic Value of S&P & Nasdaq Contact Us

हिन्दी

← Back to all stocks

CannLabs, Inc. CANL OTC

Other OTC • Healthcare • Drug Manufacturers - Specialty & Generic • US • USD

SharesGrow Score

SharesGrow Intrinsic Value

Negative cash flow

CannLabs, Inc. (CANL) is a Drug Manufacturers - Specialty & Generic company in the Healthcare sector, currently trading at $0.00. It has a SharesGrow Score of 78/100, indicating a strong investment profile with 5 out of 7 criteria passed.

Financials: revenue is $4M, +21.2%/yr average growth. Net income is $869,171, growing at +7.9%/yr. Net profit margin is 19.8% (healthy). Gross margin is 47% (-10.9 pp trend).

Balance sheet: total debt is $0 against $2M equity (Debt-to-Equity (D/E) ratio 0, conservative). Current ratio is 23.93 (strong liquidity). Debt-to-assets is 0%. Total assets: $3M.

SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 83/100 (Pass), Past 100/100 (Pass), Health 100/100 (Pass), Moat 28/100 (Fail), Future ?/100 (Fail), Income 70/100 (Pass).

CANL SharesGrow Score Overview

80/100

SharesGrow Score

Strong investment profile

View full scorecard →

VALUE 100/100

Valuation — P/E, PEG, Forward PEG

GROWTH 83/100

Financials — average growth

PAST 100/100

strong — trend

HEALTH 100/100

Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is

MOAT 28/100

Gross margin is + market cap

FUTURE 0/100

Analyst outlook — as buy

INCOME 70/100

Net profit margin is

Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — CANL

CANL trades at a trailing Price-to-Earnings (P/E) of N/A (S&P 500 average ~25). Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.

View details →

CANL: +21.2%/yr revenue is, +7.9%/yr Net income is average growth. > 5%/yr — strong. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.

View details →

CANL: 4 / 4 years profitable. strong — 100%. Score = 4 / 4 × 100. ≥ 80 = Pass.

View details →

Balance sheet CANL: Debt-to-Equity (D/E) ratio 0 (conservative), Current ratio is 23.93 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.

View details →

CANL: Gross margin is 47% (-10.9 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 28/100. ≥ 70 = Pass.

View details →

No analyst coverage available for this stock.

CANL: Net profit margin is 19.8%. healthy (≥15%). Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.

View details →

Stock Chart & Stats

Market Data

52-Week Range0.0001-0.01

Volume100

Avg Volume (30D)660

Market Cap$93.32K

Beta (1Y)5.59

Share Statistics

EPS (TTM)0.00

Shares Outstanding$813.16M

IPO Date2014-06-13

Employees37

CEOMark C. Mirken

Financial Highlights & Ratios

Revenue (TTM)$4.39M

Gross Profit$2.06M

EBITDA$880.66K

Net Income$869.17K

Operating Income$872.24K

Total Cash$651.03K

Net Debt$-651.03K

Total Assets$3.25M

Price / Earnings (P/E)0.1

Price / Sales (P/S)0.02

Analyst Forecast

Company Info

CountryUS

ExchangeOther OTC

CurrencyUSD

ISINUS13767T1025

Price Chart

CANL

CannLabs, Inc. ↗ · Other OTC

Healthcare • Drug Manufacturers - Specialty & Generic

0.00 52WK RANGE 0.01

People Also View

China Infrastructure Construction Corp.

Bionoid Pharma Inc.

Groove Botanicals, Inc.

Canntab Therapeutics Limited

Eli Lilly and Company

Johnson & Johnson

Roche Holding AG

Contact Us

🎓

SharesGrow Academy

Learn how to calculate Intrinsic Value and find undervalued stocks.

Weekly live sessions

📧 [email protected]

📞 +65 8912 8000

Send us a message